Satoshi Oka

Satoshi Oka

Auto-generated profile, based on publicly available information

Satoshi Oka

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2021 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
SOSatoshi Oka
Satoshi Oka
TKTakahiko Kai
Takahiko Kai
KHKatsuomi Hoshino
Katsuomi Hoshino
KWKazunori Watanabe
Kazunori Watanabe
JNJun Nakamura
Jun Nakamura
AWAkinori Watanabe
Akinori Watanabe
Background: Diabetes mellitus-related cardiomyopathy (DMCMP), defined as left ventricular (LV) dysfunction caused by hyperglycemia in the absence of coronary artery disease, leads to heart failure (HF). Previous studies have shown that treatment with sodium-glucose co-transporter 2 inhibitor (SGLT2i) reduces the risk of exacerbation of HF. The beneficial effects of SGLT2i on HF depend not only on indirect actions such as osmotic diuresis but also on direct actions on the myocardium, leading to improvements in LV function. However, it remains unclear whether SGLT2i treatment is equally effective in any phase of DMCMP. The aim of this observational study was to compare the efficacy of SGLT2i treatment on LV dysfunction between early and advanced DMCMP. Methods: Thirty-five symptomatic non-ischemic HF patients with LV ejection fraction > 40% and type 2 diabetes mellitus (T2DM) treated with empagliflozin (EMPA group) and 20 controls treated without SGLT2i were enrolled. According to the myocardial extracellular volume fraction (ECV), a reliable marker of cardiac fibrosis quantified by cardiac magnetic resonance, the EMPA group was further divided into early DMCMP (n = 16, ECV ≤ 30%) and advanced DMCMP (n = 19, ECV > 30%) groups and followed up prospectively. Echocardiography was performed at baseline and after 12 months. LV function assessed as LV global longitudinal strain (LVGLS) and the ratio of early diastolic mitral inflow velocity to early diastolic mitral annular velocity (E/e′) were compared. Results: ECV was strongly correlated with T2DM duration (r2 = 0.65, p < 0.001). At baseline, each group had a similar background. After 12 months, the EMPA group, especially the early DMCMP group, showed remarkable improvements in LVGLS (ΔLVGLS: 2.9 ± 3.0% (EMPA) vs. 0.6 ± 2.2% (controls), p = 0.005, and 4.6 ± 1.5% (early DMCMP) vs. 1.6 ± 3.3% (advanced DMCMP), p = 0.003) and E/e′ (ΔE/e′: − 1.5 ± 4.7 vs. − 0.3 ± 3.0, p = 0.253, and − 3.4 ± 5.5 vs. − 0.1 ± 3.5, p = 0.043). Conclusions: The positive effects of empagliflozin on LV dysfunction were more remarkable in early than in advanced DMCMP. Early intervention of SGLT2i for DMCMP may be preferable.

1 June 2018 in Cardiovascular Endocrinology & Metabolism
Verified
Journal Article
Open access
SOSatoshi Oka
Satoshi Oka
JDJuntaro Deyama
Juntaro Deyama
KUKen Umetani
Ken Umetani
THTomoko Harama
Tomoko Harama
TSTakuya Shimizu
Takuya Shimizu
MNMasahiko Nakamura
Masahiko Nakamura
Background: Glycemic variability (GV) induces coronary microcirculatory disturbance and myocardial damage in diabetic patients with acute myocardial infarction. However, in nondiabetic acute myocardial infarction patients, the relationship between GV and myocardial damage remains unclear. Patients and methods: We investigated GV with a continuous glucose monitoring system in nondiabetic ST-segment elevation myocardial infarction patients treated with emergent percutaneous coronary intervention. GV was expressed as the mean amplitude of glycemic excursions (MAGE). Myocardial damage was estimated by myocardial blush grade and ST-segment resolution (STRes). STRes was defined as complete (>70%), partial (30–70%), or none (<30%). Results: Consecutive patients ( n =73) were enrolled and classified into a lower or higher MAGE group on the basis of the median MAGE. The higher MAGE group showed lower levels of myocardial blush grade (2.41±0.76 vs. 1.72±0.85, P =0.001) and STRes (complete: 56.8 vs. 33.3%, P =0.044; partial: 32.4 vs. 36.1%, P =0.741; none: 10.8 vs. 30.6%, P =0.037). Conclusion: GV was associated with myocardial damage after percutaneous coronary intervention in nondiabetic ST-segment elevation myocardial infarction patients.

10 June 2023 in Heart Rhythm
Verified
Journal Article
Closed access
SOSatoshi Oka
Satoshi Oka
NUNobuhiko Ueda
Nobuhiko Ueda
KIKohei Ishibashi
Kohei Ishibashi
TNTakashi Noda
Takashi Noda
YMYuichiro Miyazaki
Yuichiro Miyazaki
KKKengo Kusano
Kengo Kusano

30 January 2021 in International Heart Journal
Verified
Journal Article
Closed access
PDF file
SOSatoshi Oka
Satoshi Oka
TKTakahiko Kai
Takahiko Kai
KHKatsuomi Hoshino
Katsuomi Hoshino
KWKazunori Watanabe
Kazunori Watanabe
JNJun Nakamura
Jun Nakamura
AWAkinori Watanabe
Akinori Watanabe
Tachycardia-induced cardiomyopathy (TIC) is a potentially reversible cardiomyopathy caused by tachyarrhythmia. For atrial flutter (AFL) -induced TIC, a rhythm control strategy, such as catheter ablation, has been recommended. However, the efficacy of rate control has remained unclear due to the difficulty of achieving control using arrhythmic medications. We prospectively assessed 47 symptomatic heart failure (HF) patients with left ventricular ejection fraction (LVEF) < 50% and suspected persistent AFL-induced TIC. Patients were divided into the rhythm control strategy (n = 22; treatment with catheter ablation or electrical cardioversion) and rate control strategy (n = 25; treatment with bisoprolol) groups. The latter was further divided into the strict rate control strategy (average heart rate < 80 bpm) and lenient rate control strategy (average heart rate < 110 bpm) subgroups. The primary outcome was left ventricular (LV) function recovery, which was defined as an increase in LVEF ≥ 20% or to a value of ≥ 55% after 6 months. In the rhythm control strategy group, more patients achieved LV function recovery after 6 months (95.2% versus 60.9%, P = 0.010). The cumulative incidence of worsening HF events was significantly higher in the rate control strategy group than in the rhythm control strategy group (hazard ratio, 4.66; 95% confidence interval, 1.01-21.57). The subgroup study revealed the advantage of the strict rate control strategy for achieving LV function recovery (83.3% versus 36.4%, P = 0.036). The rate control strategy was significantly inferior to the rhythm control strategy for the LV function recovery in TIC patients with persistent AFL. Our findings suggest that the strict rate control strategy should be aimed if the rhythm control strategy cannot be performed.

1 February 1994 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
YMYuji Murata
Yuji Murata
EQEdward J. Quilligan
Edward J. Quilligan
YNYuko Ninomiya
Yuko Ninomiya
AWAkihiko Wakatsuki
Akihiko Wakatsuki
NMNaoki Masaoka
Naoki Masaoka
KFKeiya Fujimori
Keiya Fujimori

12 June 2024 in HeartRhythm Case Reports
Verified
Journal Article
Open access
SOSatoshi Oka
Satoshi Oka
TKTsukasa Kamakura
Tsukasa Kamakura
SKShihomi Kirihara
Shihomi Kirihara
TITakamasa Iwai
Takamasa Iwai
SNSatoshi Nagase
Satoshi Nagase
KKKengo Kusano
Kengo Kusano